Literature DB >> 34161627

Peripheral Neuropathy Symptoms, Pain, and Functioning in Previously Treated Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone.

Larysa Sanchez1, Xavier Leleu2, Jennifer L Beaumont3, Hailin Yu3, Stacie Hudgens3, Maryana Simonova4, Holger W Auner5, Hang Quach6, Sosana Delimpasi7, Ivan Špička8, Ludĕk Pour9, Iryna Kriachok10, Meletios A Dimopoulos11, Ganna Usenko12, Roman Hájek13, Reuben Benjamin14, Dinesh Kumar Sinha15, Christopher Venner16, Thomas Illmer17, Mamta Krishnan Garg18, Don Ambrose Stevens19, Sundar Jagannath1, Moshe Levy20, Larry D Anderson21, Nizar Jacques Bahlis22, Thierry Facon23, Michele Cavo24, Yi Chai25, Xiwen Ma25, Shijie Tang25, Hoyee Leong25, Jatin Shah25, Sharon Shacham25, Michael Kauffman25, Paul Richardson26, Sebastian Grosicki27.   

Abstract

Entities:  

Year:  2021        PMID： 34161627     DOI： 10.1002/ajh.26282

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  2 in total

1.  Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patients.

Authors:  Mengmeng Dong; Jinna Zhang; Xiaoyan Han; Jingsong He; Gaofeng Zheng; Zhen Cai
Journal:  Sci Rep       Date:  2022-06-16       Impact factor: 4.996

2.  Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial.

Authors:  Michael Dolph; Gabriel Tremblay; Hoyee Leong
Journal:  Pharmacoeconomics       Date:  2021-08-09       Impact factor: 4.981
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.